E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Asthma (an illness that causes breathing difficulty) that is not fully controlled, so that episodes of breathing difficulty are still occuring despite the use of other available treatments |
Asma (enfermedad que causa dificultad para respirar) no está totalmente controlada, por lo que los episodios de dificultad respiratoria aún se producen a pesar del uso de otros ttos. disponibles. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Respiratory Tract Diseases [C08] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10003553 |
E.1.2 | Term | Asthma |
E.1.2 | System Organ Class | 10038738 - Respiratory, thoracic and mediastinal disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the safety and tolerability of two dosing regimens of benralizumab for adult and adolescent patients. |
Evaluar la seguridad y tolerabilidad de 2 pautas posológicas de benralizumab en pacientes adultos y pacientes adolescentes |
|
E.2.2 | Secondary objectives of the trial |
1.To evaluate the effect of two dosing regimens of benralizumab on asthma exacerbations. 2.To evaluate the effect of two dosing regimens of benralizumab on health care utilization and work and productivity loss. 3.To assess the effect of two dosing regimens of benralizumab on asthma related and general health-related quality of life. 4.To assess the effect two dosing regimens of benralizumab on asthma control. 5.To evaluate the pharmacokinetics and immunogenicity of two dosing regimens of benralizumab. 6.To assess the effect of two dosing regimens of benralizumab on pulmonary function. 7.To assess the impact of two dosing regimens of benralizumab on blood eosinophil levels. 8.To evaluate the effect of two dosing regimens of benralizumab on concomitant asthma controller medications. |
1. Evaluar el efecto de 2 pautas posológicas de benralizumab sobre las exacerbaciones del asma. 2. Evaluar el efecto de dos pautas posológicas de benralizumab sobre la utilización de recursos sanitarios, la actividad laboral y la pérdida de productividad laboral 3. Evaluar el efecto de 2 pautas posológicas de benralizumab sobre la calidad de vida relacionada con el asma y la salud general 4. Evaluar el efecto de dos pautas posológicas de benralizumab sobre el control del asma 5. Evaluar la farmacocinética e inmunogenicidad de 2 pautas posológicas de benralizumab 6. Evaluar el efecto de 2 pautas posológicas de benralizumab sobre la función pulmonar 7. Evaluar el impacto de 2 pautas posológicas de benralizumab sobre los niveles sanguíneos de eosinófilos 8. Evaluar el efecto de dos pautas posológicas de benralizumab sobre las medicaciones concomitantes para el control del asma. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Informed consent (and/or assent as applicable locally) for study participation must be obtained prior to any study related procedures being performed (local regulations are to be followed in determining the assent/consent requirements for children and parent(s)/guardian(s)) and according to international guidelines and/or applicable European Union guidelines. 2. Female and male patients who completed the double-blind treatment period in a predecessor study on benralizumab or matching placebo. 3. Women of childbearing potential (WOCBP) must agree to use a highly effective form of birth control throughout the study duration and for 16 weeks after the last dose of Invesigational Product (IP) 4. For WOCBP only: Have a negative urine pregnancy test prior to administration of IP at Visit 1. 5. All male patients who are sexually active must agree to use a method of contraception from the first dose of IP until 16 weeks after their last dose. The method of contraception must be consistent with local regulations, but at a minimum is to use a condom during sexual intercourse. |
1. Otorgar el consentimiento informado (y/o asentimiento según proceda localmente) para la participación en el ensayo antes de la realización de cualquier procedimiento relacionado con el ensayo (se debe seguir la normativa local a la hora de determinar los requisitos en cuanto asentimiento/consentimiento para niños y padre(s)/tutor(es)) y en conformidad con las directrices internacionales y/o las directrices aplicables en la Unión Europea. 2. Los pacientes hombres y mujeres que hayan completado el período de tratamiento en doble ciego con benralizumab o placebo equiparable en doble ciego en un ensayo predecesor. 3. Las mujeres potencialmente fértiles (MF) deben utilizar un método anticonceptivo muy eficaz durante toda la duración del ensayo y durante 16 semanas después de la última dosis del PI. 4. Solo en mujeres potencialmente fértiles: Tener un resultado negativo en una prueba de embarazo antes de la administración del PI en la visita 1. 5. Todos los pacientes varones que sean sexualmente activos deben aceptar utilizar un método anticonceptivo de doble barrera (preservativo con espermicida) desde la primera dosis del PI hasta 16 semanas después de su última dosis. |
|
E.4 | Principal exclusion criteria |
1.Any disorder including but not limited to pulmonary, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric or major physical impairment that is not stable in the opinion of the Investigator and could: -Affect the safety of the patient throughout the study -Influence the findings of the studies or their interpretations -Impede the patient?s ability to complete the entire duration of study 2.A helminth parasitic infection diagnosed during a predecessor study that has either not been treated, has been incompletely treated or has failed to respond to standard of care therapy 3.Any clinically significant change in physical examination, vital signs, electrocardiogram (ECG), haematology, clinical chemistry, or urinalysis during a predecessor study which in the opinion of the investigator may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or interfere with the patient?s ability to complete the entire duration of the study 4.Current malignancy or malignancy that developed during a predecessor study (subjects that had basal cell carcinoma, localized squamous cell carcinoma of the skin which was resected for cure, or in situ carcinoma of the cervix that has been treated/cured will not be excluded). |
1. Cualquier trastorno, como por ejemplo: pulmonar, cardiovascular, gastrointestinal, hepático, renal, neurológico, musculoesquelético, infeccioso, endocrino, metabólico, hematológico, psiquiátrico, o deterioro físico importante que no se encuentre estable en la opinión del investigador y que pudiera: - Afectar a la seguridad del paciente durante el ensayo - Influir en los resultados de los estudios o en su interpretación - Impedir que el paciente pueda completar toda la duración del ensayo 2. Infección parasitaria helmíntica diagnosticada durante el ensayo predecesor que no haya sido tratada, haya sido incompletamente tratada o no haya respondido al tratamiento de referencia 3. Cualquier cambio clínicamente significativo en la exploración física, constantes vitales, ECG, hematología, bioquímica o análisis de orina durante el ensayo predecesor que, en la opinión del investigador, pudiera suponer un riesgo para el paciente debido a su participación en el ensayo o influir en los resultados del ensayo o en la capacidad del paciente para completar toda la duración del ensayo 4. Tumor maligno actual o tumor maligno desarrollado durante un ensayo predecesor (no se excluirán a aquellos pacientes con carcinoma basocelular, carcinoma de células escamosas localizado de la piel resecado para curación o carcinoma in situ de cérvix que se hayan tratado/curado). |
|
E.5 End points |
E.5.1 | Primary end point(s) |
- Number of Adverse Events/Serious Adverse Events (AEs/SAEs) - Laboratory variables - Electrocardiogram (ECG) - Physical Examination |
- Número de AA y AAG - Variables de laboratorio - ECG - Exploración física |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
56 weeks in adult patients 108 weeks in adolescent patients |
56 semanas en pacientes adultos 108 semanas en pacientes adolescentes |
|
E.5.2 | Secondary end point(s) |
- Annual asthma exacerbation rate, where an asthma exacerbation is defined by a worsening of asthma requiring the use of systemic corticosteroids for at least 3 days, and/or an in patient hospitalization, and/or an emergency department or urgent care visit - Work Productivity and Activity Impairment Questionnaire plus Classroom Impairment Questions (WPAI+CIQ) - Hospitalizations, Emergency Department (ED) visits, urgent care visits and all other outpatient visits due to asthma - Standardised Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ(S)+12) - European Quality of Life-5 Dimensions (EQ-5D-5L) questionnaire - Asthma Control Questionnaire 6 (ACQ-6) - Pharmacokinetic (PK) parameters - Anti-drug antibodies (ADA) - Pre-bronchodilator Forced expiratory volume in 1 second (FEV1) and post-bronchodilator FEV1 at the study centre - Blood eosinophils - Total daily inhaled steroid dose - Number of other daily asthma controller medications |
- Tasa anual de exacerbaciones del asma, donde una exacerbación del asma se define como un empeoramiento del asma que requiere el uso de corticosteroides sistémicos durante al menos 3 días y/o la hospitalización y/o visita al servicio de urgencias/urgencias ambulatorias. - WPAI+CIQ - Hospitalizaciones, visitas al servicio de urgencias, visitas a urgencias ambulatorias y todas las visitas ambulatorias debidas al asma - AQLQ(S)+12 - EQ-5D-5L - ACQ-6 - Parámetros FC - Anticuerpos contra el fármaco (ACF) - FEV1 antes del broncodilatador y FEV1 después del broncodilatador en el centro del ensayo - Eosinófilos en sangre - Dosis diaria total de esteroide inhalado - Número de otras medicaciones concomitantes diarias para el control del asma |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
56 weeks in adult patients 108 weeks in adolescent patients |
56 semanas en pacientes adultos 108 semanas en pacientes adolescentes |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Tolerability |
Tolerabilidad |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Estudio abierto para adolescentes de la UE |
Open study for EU adolescents |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 12 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 236 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Australia |
Brazil |
Bulgaria |
Canada |
Chile |
Czech Republic |
France |
Germany |
Italy |
Japan |
Korea, Republic of |
Mexico |
Peru |
Philippines |
Poland |
Russian Federation |
South Africa |
Spain |
Sweden |
Turkey |
Ukraine |
United Kingdom |
United States |
Vietnam |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS |
Última visita del último paciente |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | 14 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 7 |
E.8.9.2 | In all countries concerned by the trial days | 0 |